To assess the clinical effectiveness, cost-effectiveness and adverse events of bupropion sustained-release (BSR) and nicotine replacement therapy (NRT) for smoking cessation.
Outcomes assessed in the review
The main clinical outcome measure assessed was the number of participants who were not smoking at 6, 12 or more months after the start of therapy. In addition, the incidence and severity of all adverse events were included in the review.
How were decisions on the relevance of primary studies made?
Two reviewers independently screened all the titles and abstracts for relevance. Full papers were obtained and the relevance of each article was assessed according to predefined criteria. Any discrepancies were resolved by consensus, consulting a third reviewer if necessary. Non-English language papers were not selected for inclusion in the review.
Assessment of study quality
The quality of the systematic reviews was assessed using criteria developed for DARE; the quality of the RCTs was assessed using criteria based on CRD report 4 (see Other Publications of Related Interest). Checklists for assessing the quality of studies that reported adverse events were provided in an appendix. One reviewer assessed the quality of the included studies, while another reviewer checked it independently. Any discrepancies were resolved by consensus, consulting a third reviewer if necessary.
Data extraction
One reviewer extracted relevant data into an Access database, while a second reviewer independently checked the accuracy. Details of the studies, study design, participants, interventions and results were tabulated. 
Methods of synthesis
How were the studies combined? For the assessment of clinical effectiveness, the data were pooled where possible using Peto's fixed-effect model and/or a random-effects model. Odds ratios (ORs) with 95% confidence intervals (CIs) were reported. A narrative summary was provided for the assessment of adverse events and safety.
How were differences between studies investigated?
The authors examined heterogeneity between the studies using a chi-squared test. Where possible, subgroup analyses were conducted for different participant groups.
Results of the review
To assess clinical effectiveness, 3 systematic reviews and 13 individual RCTs (including 2 unpublished RCTs) were included in the review. Four systematic reviews and 112 individual studies relating to adverse events and safety were also included.
Overall, the quality of the systematic reviews and individual RCTs included in the review was good, while the quality of the data on adverse effects and safety were variable.
Two systematic reviews and 7 RCTs (including 2 unpublished RCTs) assessed the effectiveness of NRT. NRT as an aid to smoking cessation was found to be more effective than placebo: the OR was 1.74 (95% CI: 1.64, 1.86) when using Peto's method or 1.79 (95% CI: 1.65, 1.93) when using a random-effects model. The results for abstinence at 12 months or longer were similar. The majority of data came from studies investigating the use of NRT gum and NRT patches, although there were no data to indicate that other forms of NRT were less efficacious. In addition, there were no data to indicate subgroup differences in the response to NRT.
Two systematic reviews, 3 RCTs and 4 unpublished trials assessed the effectiveness of BSR. BSR as an aid to smoking cessation was also found to be more effective than placebo: the ORs were 2.52 (95% CI: 1.99, 3.19) and 2.45 (95% CI: 1.72, 3.49) for fixed-effect (Peto) and random-effects models, respectively. The results were similar for all durations of follow-up. There was evidence from single subgroup populations that BSR was as effective in smokers with chronic obstructive pulmonary disease, cardiovascular disease and in those who had failed in the past to achieve abstinence with BSR, as in the general smoking population.
Evidence to support one intervention over the other was relatively weak.
Overall, the incidence of adverse events with NRT was very low, while the review identified seizure as the most significant and important potential adverse effect of BSR.
